A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Acerta Pharma BV
Acerta Pharma BV
Incyte Corporation
Incyte Corporation
Celgene
Novartis
University of South Florida
INSYS Therapeutics Inc